AOD-9604 is the synthetic C-terminal fragment 176-191 of human growth hormone, supplied as a research peptide. It isolates the lipolytic C-terminal domain of growth hormone without the somatogenic and insulin-resistance effects of the full molecule.
This guide is written for researchers working with AOD-9604 (HGH Fragment 176-191) strictly for in-vitro or preclinical fat-metabolism work. You will find the mechanistic evidence base (which has not been refreshed by a major human trial since the pre-2020 MetaOD-006 dataset) and how AOD-9604 compares to structurally related peptides.
Key Takeaways
- AOD-9604 is a 16-amino-acid C-terminal fragment of human growth hormone that stimulates lipolysis without raising IGF-1 levels at research doses
- The evidence base is rodent-dominated and pre-2010; the only human trial (METAOD006) showed no significant weight loss versus placebo
- Verify batch-specific certificates of analysis confirming ≥98% HPLC purity before use
- AOD-9604 differs mechanistically from GHRH analogues such as tesamorelin and CJC-1295, which raise IGF-1 as part of their intended signal
What Is AOD-9604? The HGH Fragment 176-191 Explained
AOD-9604 is a synthetic 16-amino-acid peptide corresponding to residues 176–191 of the C-terminus of human growth hormone, with a molecular weight of approximately 1,817.1 Da and the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. It is not full-length HGH and does not replicate HGH's somatogenic or insulin-resistance effects; it isolates the lipolytic C-terminal domain only.
Nomenclature and identity
In the research literature, "AOD-9604" and "HGH Fragment 176-191" are used interchangeably. "AOD" is the original Metabolic Pharmaceuticals development code for the anti-obesity drug candidate. A tyrosine residue was added at the N-terminus of the native 177–191 sequence to improve stability, which is why some older papers refer to the parent fragment as hGH 177-191 while the AOD-9604 analogue is catalogued as 176-191.
Structural features relevant to procurement
The peptide contains two cysteine residues (positions 182 and 189 of the parent HGH numbering) that form an intramolecular disulphide bridge, producing the small cyclic structure characteristic of the C-terminal lipolytic domain. Research-grade vials are typically the acetate salt, lyophilised, at ≥98% HPLC purity. This specification is consistent across international analytical reference suppliers such as Cayman Chemical and research vendors quoting 99%+ purity.
For readers building a wider GH-axis comparison, the tesamorelin research peptide profile and the CJC-1295 peptide page cover GHRH-class agents that act upstream of endogenous HGH secretion, in contrast to AOD-9604's direct fragment-level mechanism.
Mechanism of Action: How AOD-9604 Affects Fat Metabolism
AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue without activating the IGF-1 axis or producing full growth hormone receptor agonism. This pharmacological separation is the central reason the fragment was developed as an anti-obesity candidate distinct from recombinant somatropin. The C-terminal 176-191 sequence retains the fat-metabolism signal of HGH while shedding the somatogenic and diabetogenic activity associated with the full molecule.
Beta-3 adrenergic signalling and the lipolytic switch
Preclinical work attributes AOD-9604's lipolytic effect to upregulation of beta-3 adrenergic receptor (β3-AR) expression in adipocytes. This upregulation increases cyclic AMP turnover and drives hormone-sensitive lipase activity in white and brown fat depots. In parallel, the peptide suppresses lipogenic enzyme activity, shifting adipocyte energy balance toward fatty acid release rather than triglyceride storage.
The disulphide bridge between Cys182 and Cys189 holds the cyclic conformation that this receptor-level activity depends on. Reduction of that bond abolishes the lipolytic signal in vitro.
Decoupling from the IGF-1 pathway
Unlike intact HGH, AOD-9604 does not bind the GH receptor with full agonist activity and does not stimulate hepatic IGF-1 production at lipolytic doses. In the foundational Heffernan et al. (2001) work in obese Zucker rats, 14 days of dosing at 500 µg/kg/day produced roughly a 50% reduction in adipose mass without significant change in blood glucose or serum IGF-1. Wu and colleagues had earlier mapped the lipolytic domain to the C-terminus of GH, providing the rationale for isolating residues 177-191 as a stand-alone fragment.
For researchers building a fat-metabolism comparator panel, the tesamorelin research peptide acts upstream as a GHRH analogue driving endogenous GH pulsatility, and CJC-1295 prolongs that GHRH signal. Both produce IGF-1 elevation that AOD-9604 specifically avoids. This mechanistic distinction is the basis for the comparison table later in this guide.
AOD-9604 vs Related Peptides: Comparison Table (2026)
AOD-9604 is the only peptide in this comparison panel that produces lipolysis without measurable IGF-1 elevation at research doses. The table below sets it against three GH-axis comparators researchers most often evaluate alongside it.
| Parameter | AOD-9604 | Tesamorelin | CJC-1295 | Somatropin (rHGH) |
|---|---|---|---|---|
| Mechanism | C-terminal GH fragment (177-191); direct adipocyte cAMP/HSL activation | GHRH(1-44) analogue; stimulates endogenous GH pulse | GHRH analogue; with DAC, albumin-bound depot | Full-length 191-aa recombinant GH; GHR agonist |
| Half-life (subcut.) | ~30 min (rodent) | ~26 min | ~30 min (no DAC); ~8 days (with DAC) | ~2-3 h |
| IGF-1 effect | No significant rise at lipolytic doses | Marked rise | Marked, sustained rise (DAC) | Marked rise |
| Primary research application | Adipocyte lipolysis, fat-metabolism in vitro | Visceral adipose tissue reduction models | GH pulsatility / IGF-1 axis studies | GH deficiency reference comparator |
The mechanistic split matters for procurement decisions. Tesamorelin and CJC-1295 both raise IGF-1 as part of their intended signal, which confounds any study isolating peripheral adipocyte lipolysis from systemic GH-axis effects. AOD-9604's value as a research tool sits in that decoupling, not in any claim of superior fat-loss potency over intact GH.
Regulatory status
AOD-9604 is an investigational research compound supplied strictly for laboratory research use only. It is not an approved medicine, and its regulatory status differs between countries. Verify the applicable rules in your own jurisdiction before handling.
AOD-9604 Research Applications: What the Literature Shows
The AOD-9604 evidence base is shallow, rodent-dominated, and over a decade old. No peer-reviewed human clinical trial published between 2020 and 2026 supersedes the legacy Metabolic Pharmaceuticals dataset. The most-cited preclinical lipolysis work in obese rodent models still traces back to Heffernan and colleagues circa 2001. Researchers designing 2026 protocols should treat the entire human evidence base as pre-2010 and methodologically stale by current standards.
Preclinical signal: rodent lipolysis models
The mechanistic case for AOD-9604 rests on rodent adipocyte work showing increased lipolytic activity and reduced lipogenesis without the IGF-1 elevation associated with full-length growth hormone. These findings underpin every subsequent vendor monograph but have not been replicated in modern, independently funded preclinical programmes accessible via PubMed. For in-vitro fat-metabolism research, the rodent dataset remains the reference point. Translational extrapolation to human adipose tissue is unsupported by current trial data.
The METAOD006 nuance vendors omit
Metabolic Pharmaceuticals' Phase IIb trial (METAOD006, conducted 2004–2007) enrolled approximately 300 obese adults on oral AOD-9604 1 mg/day. The trial reported no statistically significant weight loss versus placebo at 24 weeks. This failure is rarely surfaced in commercial peptide marketing, yet it is the single most consequential human data point in the file.
Two interpretations coexist in the secondary literature. One is that the molecule lacks clinical efficacy at the tested dose. The other is that oral bioavailability was the limiting factor. Neither has been resolved by a Phase III programme, which had not been completed as of May 2026.
Why route of administration matters for research design
Oral peptide bioavailability is typically under 1% due to gastric proteolysis. Subcutaneous administration in preclinical models bypasses first-pass degradation entirely. Researchers replicating historical lipolysis endpoints should specify route, vehicle, and dose-normalisation explicitly. Conflating oral METAOD006 outcomes with subcutaneous rodent data is a recurring error in vendor literature.
For mechanistic comparators on the GH axis, see our notes on tesamorelin and CJC-1295, both of which carry more recent human pharmacokinetic data than AOD-9604.
Body Pharm AOD-9604: Product Specifications
Body Pharm AOD-9604 is a lyophilised research peptide, typically supplied in 2 mg and 5 mg vials at a labelled purity of ≥98% by HPLC. Researchers should request the batch-specific CoA to confirm purity, peptide content, and residual TFA (trifluoroacetic acid) or acetate counter-ion.
Storage and reconstitution
Lyophilised AOD-9604 is stable at −20 °C for approximately 24 months when sealed and protected from light, consistent with vendor stability recommendations for this class of GH-fragment peptides. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) for research handling. The reconstituted solution is generally stable at 2–8 °C for up to 28 days. Avoid freeze-thaw cycles to limit aggregation and loss of mass-spectrometric integrity. Lyophilised peptide tolerates short-term ambient excursions, which is why it typically ships dry rather than frozen.
Verifying quality
Request a batch-specific Certificate of Analysis showing HPLC purity (research-grade AOD-9604 typically certifies at ≥98%), mass-spectrometric confirmation of the expected 1,815 Da fragment, and the counter-ion form (acetate or TFA). A vial supplied without a CoA and batch number is not characterised research material. The tesamorelin research peptide and CJC-1295 peptide pages sit in the same cluster for comparator work.
For research use only. Not for human or veterinary therapeutic use. Review mechanistic comparators such as the tesamorelin research peptide and CJC-1295 peptide pages for GH-axis context.
AOD-9604 and Related Peptides: Expanding Your Research Stack
AOD-9604 occupies a distinct mechanistic niche. It acts downstream of the GH receptor on adipocytes to stimulate lipolysis and inhibit lipogenesis, without engaging the somatotrophic axis. That distinction matters when designing comparative studies, because the peptides most often co-investigated with AOD-9604 work upstream at the hypothalamic-pituitary level rather than on fat cells directly.
Two GHRH analogues sit closest in the GH-axis cluster. The tesamorelin research peptide is the most clinically characterised member of the family for visceral adipose tissue endpoints, making it the natural comparator when modelling fat-depot-specific responses. The CJC-1295 peptide is investigated for sustained GH pulse amplification and is frequently paired in protocols with a ghrelin mimetic such as Ipamorelin, which acts as a selective GH secretagogue at the pituitary.
Somatropin, recombinant full-length 191-amino-acid human growth hormone, is the reference standard against which any GH-axis fragment is benchmarked. AOD-9604 corresponds to residues 176-191 of that parent molecule, retaining the putative lipolytic C-terminus while lacking the receptor-binding domains responsible for IGF-1 induction.
Combining AOD-9604 with an upstream secretagogue in an assay is a research design question about additive versus independent pathway effects, not a clinical recommendation. Any such protocol remains strictly for in-vitro or preclinical use.
Frequently Asked Questions
Is AOD-9604 the same as HGH Fragment 176-191?
Yes. AOD-9604 is a synthetic analogue of the C-terminal fragment of human growth hormone corresponding to residues 176-191, with an added tyrosine at the N-terminus to improve stability. The names "AOD-9604" and "HGH Fragment 176-191" are used interchangeably in the research literature and supplier catalogues.
What is the difference between AOD-9604 and Somatropin?
Somatropin is recombinant full-length 191-amino-acid human growth hormone. AOD-9604 contains only residues 176-191, retaining the putative lipolytic C-terminus but lacking the receptor-binding domains responsible for IGF-1 induction. The two are not pharmacologically equivalent.
How should AOD-9604 be stored after reconstitution?
Reconstituted AOD-9604 should be kept at 2–8 °C and used within the stability window indicated on the supplier's certificate of analysis. Lyophilised vials are typically shipped at ambient temperature with the recommendation to refrigerate on receipt.
Next Steps
If you are designing a fat-metabolism or GH-axis study, start by clarifying whether AOD-9604's downstream adipocyte mechanism or an upstream GHRH-class agent such as tesamorelin or CJC-1295 fits your research question. Request batch-specific certificates of analysis for your material and confirm purity before beginning work.
